血球蛋白糖化指数和糖尿病患者的快速功能下降:查尔斯的见解
Fan Zhang1, Rui Zhou1, Yan Bai2
1Department of Nephrology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Diabetes research and clinical practice
|February 22, 2025
概括
较高的血红蛋白糖化指数 (HGI) 与糖尿病患者快速功能下降 (RKFD) 的风险增加有关. 这一发现强调了HGI作为糖尿病管理中脏健康的潜在标志物.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 代谢综合征是代谢综合征的一种.
背景情况:
- 糖尿病病是糖尿病的主要并发症.
- 血红蛋白糖化指数 (HGI) 反映了血糖的变化和控制.
- 预测功能快速下降 (RKFD) 对糖尿病管理至关重要.
研究的目的:
- 调查HGI与糖尿病患者RKFD风险之间的关联.
- 确定HGI是否可以作为糖尿病患者功能下降的预测标记.
主要方法:
- 通过从测量的HbA1c中减去预测的HbA1c来计算HGI.
- 随着时间的推移,RKFD被定义为估计膜过率 (eGFR) 的30%下降.
- 使用多变量Cox比例危险模型和定向环形图来分析关联,并对混因素进行调整.
主要成果:
- 在平均4.0年的随访期间,6.3%的糖尿病患者经历了RKFD.
- 与最低HGI组相比,中等和高HGI组显示RKFD的危险比率分别增加 (1.75和2.64).
- 敏感性分析证实了这些关联的稳定性,尽管并非所有关联都达到统计学意义.
结论:
- 升高的HGI可能与糖尿病患者快速功能下降的风险更高有关.
- HGI可能代表一个有价值的生物标志物,用于识别患有糖尿病病进展风险增加的个体.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
497
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
497
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131
Factors Affecting Renal Clearance: Renal Impairment
48
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
48
Hypoglycemia and Glucagon
149
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
149
Dipeptidyl Peptidase 4 Inhibitors
163
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
163


